Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.59 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.59 |
| ▸ | MMP1 | P03956 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840065 | 0.88 | L3MBTL1 (0.68) | EPHX1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Phenethylcarbamic Acid SCHEMBL249525 | 0.83 | CA12 (0.68) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL22412530 | 0.83 | PLAAT5 (0.75) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL6032606 | 0.83 | EPHX1 (0.85) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL5839533 | 0.81 | NPC1 (0.61) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL1567251 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28010696 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL9718519 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL4459966 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL6440533 | 0.80 | CA12 (0.59) | CA12CA2CA9EPHX1PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | claimed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-0978516-A1 | 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY | SUNTORY LIMITED (JP) | 2000-02-09 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0392317-B1 | Benzimidazoles, drugs containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1996-01-03 | — | — | EP | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CA12 1703/4885CA2 1487/4885CA9 1595/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CA12 2821/4885CA2 2236/4885CA9 2912/4885 |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CA12 2559/4885CA2 829/4885CA9 2802/4885 |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CA12 2559/4885CA2 829/4885CA9 2802/4885 |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CA12 2501/4885CA2 777/4885CA9 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.